KanellosD.CharalampousMD

PubMed

• John E. Overall.
  Charalampous, K. D.> ;Neuropsychopharmacology. 2018 Apr 20
• Joseph Clayton Schoolar
  Kanellos Charalampous> ;Neuropsychopharmacology. 2014 Dec 1
• 25 citations
  Drug treatment in newly admitted schizophrenic patients.
  Mervin L. Clark, Wolfgang K. Huber, Kanellos D. Charalampous, Eustace A. Serafetinides, William Trousdale, John P. Colmore> ;Archives of General Psychiatry. 1971 Nov 1
• Absorption and excretion of thioridazine and mesoridazine in man.
  Charalampous, K. D., Johnson, P. C., Estevez, V.> ;Dis Nerv Syst. 1974 Nov
• METABOLIC FATE OF BETA-(3,4,5-TRIMETHOXYPHENYL)-ETHYLAMINE (MESCALINE) IN HUMANS: ISOLATION AND IDENTIFICATION OF 3,4,5-TRIMETHOXYPHENYLACETIC ACID.
  CHARALAMPOUS, K. D., ORENGO, A., WALKER, K. E., KINROSS-WRIGHT, J.> ;J Pharmacol Exp Ther. 1964 Aug
• ANTIDEPRESSANTS -- A REEVALUATION.
  CHARALAMPOUS, K. D.> ;Med Times. 1964 Dec
• INTRAVENOUS FLUID, HALLUCINATIONS AND TREMOR.
  CHARALAMPOUS, K. D.> ;Med Rec Ann. 1963 Dec
• THE LONG-TERM CARE OF THE CHRONIC MENTALLY ILL PATIENT, A MEDICAL APPROACH.
  CHARALAMPOUS, K. D.> ;Med Rec Ann. 1963 Dec
• HALLUCINOGENS. TOOLS FOR RESEARCH OR THERAPEUTIC AGENTS.
  CHARALAMPOUS, K. D., KINROSS-WRIGHT, J.> ;Tex Med. 1963 Sep
• A psychopharmacology research unit.
  KINROSS-WRIGHT, J., CHARALAMPOUS, K. D.> ;Dis Nerv Syst. 1963 May
• Severe mental depressions.
  CHARALAMPOUS, K. D.> ;Med Rec Ann. 1963 Apr
• Pseudoneurotic schizophrenia.
  CHARALAMPOUS, K. D.> ;Med Rec Ann. 1963 May
• Psychosis following the use of amphetamines.
  CHARALAMPOUS, K. D., HUG, A.> ;Med Rec Ann. 1963 Feb
• Insights into physician retirement.
  Liss, S. E., Cohen, I. M., Charalampous, K. D.> ;Tex Med. 2001 Sep
• Double-blind placebo-controlled multicenter evaluation of the efficacy and safety of nomifensine in depressed outpatients.
  Goldstein, B. J., Brauzer, B., Kentsmith, D., Rosenthal, S., Charalampous, K. D.> ;J Clin Psychiatry. 1984 Apr
• Absorption and excretion of tritiated haloperidol in man. (A preliminary report).
  Johnson, P. C., Charalampous, K. D., Braun, G. A.> ;Int J Neuropsychiatry. 1967 Aug
• Metabolic fate of beta-(3,4-dimethoxyphenyl)-ethylamine in man.
  Charalampous, K. D., Tansey, L. W.> ;J Pharmacol Exp Ther. 1967 Feb
• Metabolic fate of mescaline in man.
  Charalampous, K. D., Walker, K. E., Kinross-Wright, J.> ;Psychopharmacologia. 1966
• A comprehensive intensive treatment program for alcoholism.
  Dunn, R. B., Smith, J. W., Lemere, F., Charalampous, K. D.> ;Southwest Med. 1971 May
• Comparison of metabolism of mescaline and 3,4-dimethoxyphenylethylamine in humans.
  Charalampous, K. D.> ;Behav Neuropsychiatry. 1971 Feb 01
• Studies of C-14-protriptyline man: plasma levels and excretion.
  Charalampous, K. D., Johnson, P. C.> ;J Clin Pharmacol J New Drugs. 1967 Mar 01
• Drug culture in the seventies.
  Charalampous, K. D.> ;Am J Public Health. 1971 Jun
• A clinical trial of a-methyl-para-tyrosine in mentally ill patients.
  Charalampous, K. D., Brown, S.> ;Psychopharmacologia. 1967 Oct 06
• Amoxapine: a clinical evaluation in depressive syndromes.
  Charalampous, K. D.> ;Curr Ther Res Clin Exp. 1972 Oct 01
• Clorazepate dipotassium: a new benzodiazepine antianxiety agent.
  Charalampous, K. D., Tooley, W., Yates, C.> ;J Clin Pharmacol New Drugs. 1973 Feb 01
• Join now to see all